Krystn Hammond

Krystn leads the valuation practice in New York and for life sciences nationally.  

She has over 17 years of experience advising pharmaceutical and life sciences clients on transactions and tax restructurings, including acquisitions, divestitures, spin-offs, and intellectual property migrations. Her experience spans across industry subsectors, including big pharma, biotech, medical device/diagnostics, generic, specialty, animal health, OTC/consumer, and services, with transaction sizes ranging from $50 million to in excess of $70 billion.

Prior to joining GT, Krystn worked as a healthcare investment banker focused on strategic M&A at Stifel, via its acquisition of Torreya Capital, advising on transactions across generics, specialty pharma, complex formulations, and infectious disease.

Previously, Krystn was a Director in PwC's Deals practice focused on life sciences, and also led the firm's middle market clients and opportunities business development initiative for the sector in the New York metro region.

Outside of work, Krystn serves on the Education Committee for American Ballet Theatre, and previously served as audit committee chair and treasurer of an international ballet scholarship competition as well as on the Junior Council for American Ballet Theatre. She is a member of the Apollo Circle of the Metropolitan Museum of Art.

Krystn received a bachelor’s degree in Finance and master’s degree in Accounting from the A.B. Freeman School of Business at Tulane University. She is a CFA charter holder, a licensed CPA in the state of New York, and holds inactive FINRA Series 63 and 79 licenses in good standing.